Technical Analysis for GLSI - Greenwich LifeSciences, Inc.

Grade Last Price % Change Price Change
F 12.85 0.63% 0.08
GLSI closed up 0.63 percent on Wednesday, November 20, 2024, on approximately normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Lower Bollinger Band Walk Weakness 0.63%
Lower Bollinger Band Touch Weakness 0.63%
Lower Bollinger Band Walk Weakness 3.88%
Below Lower BB Weakness 3.88%
Lower Bollinger Band Touch Weakness 3.88%
20 DMA Resistance Bearish 2.31%
50 DMA Resistance Bearish 2.31%
Wide Range Bar Range Expansion 2.31%
Lower Bollinger Band Walk Weakness 2.31%

   Recent Intraday Alerts

Alert Time
Down 1% about 20 hours ago
Up 2% about 20 hours ago
Up 1% about 20 hours ago
Rose Above Previous Day's High 1 day ago
Up 5% 1 day ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Greenwich LifeSciences, Inc. Description

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Acid Immunotherapy Surgery Cancer Treatment Breast Cancer Clinical Trial Treatment Of Breast Cancer Her2 Cancer Center Her2/Neu

Is GLSI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.44
52 Week Low 8.0
Average Volume 28,302
200-Day Moving Average 14.44
50-Day Moving Average 13.87
20-Day Moving Average 13.55
10-Day Moving Average 13.33
Average True Range 0.87
RSI (14) 43.50
ADX 14.16
+DI 13.88
-DI 19.66
Chandelier Exit (Long, 3 ATRs) 12.19
Chandelier Exit (Short, 3 ATRs) 14.49
Upper Bollinger Bands 14.71
Lower Bollinger Band 12.38
Percent B (%b) 0.2
BandWidth 17.17
MACD Line -0.28
MACD Signal Line -0.16
MACD Histogram -0.1162
Fundamentals Value
Market Cap 165.1 Million
Num Shares 12.8 Million
EPS -0.70
Price-to-Earnings (P/E) Ratio -18.36
Price-to-Sales 0.00
Price-to-Book 12.31
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.99
Resistance 3 (R3) 14.05 13.72 13.80
Resistance 2 (R2) 13.72 13.43 13.70 13.74
Resistance 1 (R1) 13.29 13.25 13.51 13.23 13.67
Pivot Point 12.96 12.96 13.07 12.94 12.96
Support 1 (S1) 12.53 12.67 12.75 12.47 12.03
Support 2 (S2) 12.20 12.49 12.18 11.96
Support 3 (S3) 11.77 12.20 11.90
Support 4 (S4) 11.71